Trial Profile
A 5-week, randomized, double-blind, placebo-controlled multi-center study of [S,S]-reboxetine in patients with postherpetic neuralgia (Phn), who are gabapentin treatment failures
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2006
Price :
$35
*
At a glance
- Drugs Esreboxetine (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Pfizer
- 21 Aug 2006 Status change
- 15 Nov 2005 New trial record.